Author

Joëlle S. Nader

Centre National de la Recherche ScientifiqueORCID 0000-0002-0378-3966Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Jean‐François FonteneauiD· 2 shared Nicolas BoisgeraultiD· 2 shared Aleksandr BarinoviD· 1 shared Anastassia V. KomarovaiD· 1 shared Atousa Arbabian· 1 shared Bernadette Brzezicha· 1 shared Camille Chatelain· 1 shared Chantal CombredetiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Jean‐François FonteneauORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintJun 3, 2026

A novel tumor-targeted interferon-α/-β receptor 1 antagonist increases replication of oncolytic vesicular stomatitis virus in a mouse mesothelioma model

Thomas Teja Ogor, Yann Bordat, Manon Souchard…·Jean‐François Fonteneau

This paper develops IFNAR1 antagonists that selectively block IFNAR signaling in tumor cells, enhancing VSV oncolytic activity in mesothelioma and melanoma models.

DOI 10.64898/2026.06.02.729496

mouseproteomics

𝕏 PostBluesky

ImmunologybioRxivPreprintOct 3, 2025

Disabling a key viral innate immunity antagonist converts measles vaccine into RIG-I-driven cancer immunotherapy

Aleksandr Barinov, Heidy Vera-Peralta, Joëlle S. Nader…·Frédéric Tangy

This paper modifies a measles vaccine by removing a viral protein to create a cancer immunotherapy that activates the immune system via RIG-I signaling, leading to tumor regression in multiple models.

1 citation

mousehuman

𝕏 PostBluesky